lenvatinib

1. 01:20
   x.com

   .@llovet_m, of @mountsinailiver, previews the long-term OS results of the phase 3 LEAP-012 study with lenvatinib plus pembrolizumab vs dual placebo with transarterial chemoemboliza

1. 17:51
   x.com

   🧬 EMERALD-3 exploratory analysis in HCC:
2. 02:15
   x.com

   ChromoKey Phase 2 Study Demonstrates Promising Activity of Lenvatinib + Pembrolizumab in Metastatic Chromophobe #RenalCellCarcinoma. Presented by Ilya Tsimafeyeu, MD, PhD. #ESMO26

1. 22:20
   x.com

   Getting ready for the #RapidOral session in #NETs at @myESMO #ESMO26

1. 20:00
   x.com

   OncoAlert 4Sight Abstracts to be Presented at #ESMO26

1. 20:00
   clinicaltrials.gov

   MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer

1. 20:00
   clinicaltrials.gov

   Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study

Heat now 22·Peak in the comparable set 29 (Oct 25 02:00)·Change over 24h in the comparable set +26%·Participants now 5

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.